Affiliations 

  • 1 The Leeds Bionanotechnology Group, School of Biomedical Sciences, University of Leeds, Leeds, LS2 9JT, UK. shazana.hilda@usm.my
  • 2 Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, LS9 7TF, UK
  • 3 Bioscreening Technology Group, School of Molecular and Cellular Biology, University of Leeds, Leeds, LS2 9JT, UK
  • 4 The Leeds Bionanotechnology Group, School of Biomedical Sciences, University of Leeds, Leeds, LS2 9JT, UK. P.A.Millner@leeds.ac.uk
Sci Rep, 2021 01 12;11(1):744.
PMID: 33436840 DOI: 10.1038/s41598-020-80354-6

Abstract

Carcinoembryonic antigen (CEA) is the only blood based protein biomarker at present, used for preoperative screening of advanced colorectal cancer (CRC) patients to determine the appropriate curative treatments and post-surveillance screening for tumour recurrence. Current diagnostics for CRC detection have several limitations and development of a highly sensitive, specific and rapid diagnostic device is required. The majority of such devices developed to date are antibody-based and suffer from shortcomings including multimeric binding, cost and difficulties in mass production. To circumvent antibody-derived limitations, the present study focused on the development of Affimer proteins as a novel alternative binding reagent for CEA detection. Here, we describe the selection, from a phage display library, of Affimers specific to CEA protein. Characterization of three anti-CEA Affimers reveal that these bind specifically and selectively to protein epitopes of CEA from cell culture lysate and on fixed cells. Kinetic binding analysis by SPR show that the Affimers bind to CEA with high affinity and within the nM range. Therefore, they have substantial potential for used as novel affinity reagents in diagnostic imaging, targeted CRC therapy, affinity purification and biosensor applications.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.